News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
484,360 Results
Type
Article (8024)
Company Profile (140)
Press Release (476099)
Multimedia
Podcasts (4)
Webinars (6)
Section
Business (166747)
Career Advice (304)
Deals (25738)
Drug Delivery (7)
Drug Development (52875)
Employer Resources (14)
FDA (9760)
Job Trends (8575)
News (238198)
Policy (17898)
Tag
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (485)
Accelerated approval (24)
ADA (18)
Adcomms (1)
Allergies (96)
Alliances (33157)
ALS (104)
Alzheimer's disease (973)
Antibody-drug conjugate (ADC) (262)
Approvals (10366)
Artificial intelligence (319)
ASCO (159)
Autoimmune disease (205)
Automation (28)
Bankruptcy (262)
Best Places to Work (6958)
BIO (36)
BIOSECURE Act (1)
Biosimilars (108)
BioSpace Insights (17)
Biotechnology (88)
Bladder cancer (138)
Brain cancer (28)
Breast cancer (506)
Cancer (3624)
Cardiovascular disease (217)
Career advice (245)
Career pathing (1)
CAR-T (174)
Celiac Disease (1)
Cell therapy (479)
Cervical cancer (34)
Clinical research (47837)
Collaboration (1238)
Commercialization (3)
Compensation (1444)
Complete response letters (34)
COVID-19 (754)
CRISPR (63)
C-suite (735)
Cystic fibrosis (85)
Data (5605)
Denatured (4)
Depression (102)
Dermatology (60)
Diabetes (341)
Diagnostics (4175)
Digital health (37)
Diversity (1)
Diversity, equity & inclusion (4)
Drug discovery (154)
Drug pricing (7)
Drug shortages (2)
Duchenne muscular dystrophy (163)
Earnings (73563)
Editorial (1)
Employer branding (2)
Employer resources (14)
Events (87574)
Executive appointments (697)
FDA (12360)
Fibrodysplasia Ossificans Progressiva (8)
Friedreich's ataxia (18)
Frontotemporal dementia (23)
Funding (906)
Gene editing (126)
Generative AI (9)
Gene therapy (317)
GLP-1 (289)
Government (940)
Grass and pollen (2)
Guidances (281)
Healthcare (9311)
Hematology (94)
HIV (52)
Huntington's disease (22)
IgA nephropathy (64)
Immunology and inflammation (98)
Immuno-oncology (56)
Indications (155)
Infectious disease (942)
Inflammatory bowel disease (126)
Inflation Reduction Act (4)
Influenza (84)
Intellectual property (253)
Interviews (41)
IPO (12386)
IRA (2)
Job creations (1969)
Job search strategy (235)
JPM (1)
Kidney cancer (16)
Layoffs (60)
Legal (5195)
Licensing (7)
Liver cancer (44)
Longevity (15)
Lung cancer (502)
Lymphoma (249)
Machine learning (27)
Management (3)
Manufacturing (525)
Marketing (8)
MASH (118)
Medical device (8649)
Medtech (8789)
Mergers & acquisitions (14377)
Metabolic disorders (703)
mRNA (53)
Multiple sclerosis (102)
NASH (4)
Neurodegenerative disease (220)
Neuropsychiatric disorders (38)
Neuroscience (1815)
NextGen: Class of 2026 (3150)
Non-profit (841)
Obesity (222)
Opinion (10)
Ovarian cancer (158)
Pain (170)
Pancreatic cancer (195)
Parkinson's disease (201)
Partnered (12)
Patents (471)
Patient recruitment (501)
Peanut (31)
People (41205)
Pharmaceutical (30)
Pharmacy benefit managers (8)
Phase 1 (15455)
Phase 2 (21367)
Phase 3 (14386)
Pipeline (7134)
Policy (18)
Postmarket research (1570)
Preclinical (6536)
Press Release (34)
Prostate cancer (189)
Psychedelics (7)
Radiopharmaceuticals (189)
Rare diseases (569)
Real estate (3021)
Recruiting (6)
Regulatory (14779)
Reports (19)
Research institute (580)
Resumes & cover letters (45)
Rett syndrome (41)
RNA editing (5)
RSV (48)
Schizophrenia (99)
Series A (152)
Series B (120)
Service/supplier (5)
Sickle cell disease (62)
Spinal muscular atrophy (88)
Sponsored (5)
Startups (2018)
Stomach cancer (3)
Supply chain (50)
Vaccines (317)
Venture capital (17)
Weight loss (73)
Women's health (78)
Date
Today (93)
Last 7 days (541)
Last 30 days (1612)
Last 365 days (19155)
2026 (11895)
2025 (19251)
2024 (22992)
2023 (26538)
2022 (34588)
2021 (37176)
2020 (33480)
2019 (23256)
2018 (17468)
2017 (18766)
2016 (17917)
2015 (24263)
2014 (21679)
2013 (18138)
2012 (20222)
2011 (20440)
2010 (20333)
Location
Africa (228)
Alabama (72)
Alaska (2)
Arizona (299)
Arkansas (11)
Asia (17877)
Australia (2097)
California (11843)
Canada (3114)
China (513)
Colorado (479)
Connecticut (405)
Delaware (207)
Europe (24617)
Florida (1770)
Georgia (371)
Hawaii (3)
Idaho (46)
Illinois (694)
India (48)
Indiana (314)
Iowa (14)
Japan (396)
Kansas (100)
Kentucky (30)
Louisiana (26)
Maine (26)
Maryland (1187)
Massachusetts (7803)
Michigan (306)
Minnesota (558)
Mississippi (4)
Missouri (80)
Montana (20)
Nebraska (11)
Nevada (114)
New Hampshire (60)
New Jersey (2599)
New Mexico (12)
New York (2799)
North Carolina (1262)
North Dakota (4)
Northern California (5926)
Ohio (275)
Oklahoma (14)
Oregon (18)
Pennsylvania (2239)
Puerto Rico (20)
Rhode Island (30)
South America (406)
South Carolina (76)
South Dakota (1)
Southern California (4914)
Tennessee (119)
Texas (1913)
United States (38516)
Utah (357)
Vermont (1)
Virginia (153)
Washington D.C. (38)
Washington State (918)
West Virginia (1)
Wisconsin (73)
484,360 Results for "xyphos inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
PHANES THERAPEUTICS entered into a research collaboration with Xyphos Biosciences, Inc., an Astellas Company
Phanes Therapeutics, Inc. today announced that it has entered into a research collaboration with Xyphos Biosciences, Inc. an Astellas Company.
March 6, 2023
·
2 min read
Business
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
Astellas Pharma Inc. and Poseida Therapeutics, Inc. today announced that Xyphos Biosciences, Inc., (a wholly owned subsidiary of Astellas, “Xyphos”) and Poseida have entered into a research collaboration and license agreement to develop novel convertibleCAR® programs by combining the innovative cell therapy platforms from each of the companies.
May 1, 2024
·
8 min read
Deals
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Xyphos Biosciences, Inc. (CEO: James Knighton, “Xyphos”) today announced that Astellas has acquired Xyphos.
December 26, 2019
·
5 min read
Business
AbSci Enters Biologics Development Collaboration with Xyphos Biosciences, an Astellas Company
AbSci, a pioneering synthetic biology company enabling drug discovery and biomanufacturing of next-generation biotherapeutics, today announced that it has partnered with Xyphos Biosciences, an Astellas Company, to screen and identify a variant of Xyphos’ MicAbody™ lead candidate for optimal manufacturing cell line development.
February 3, 2021
·
3 min read
Genetown
Astellas and Kelonia Therapeutics Enter into Research and License Agreement to Develop Novel Immuno-Oncology Therapeutics
Astellas Pharma Inc. and Kelonia Therapeutics announced that Xyphos Biosciences, Inc., and Kelonia have entered into a research collaboration and license agreement to develop novel Immuno-Oncology therapeutics.
February 15, 2024
·
6 min read
Press Releases
Tevogen Bio Holdings Inc. Becomes Tevogen Inc.
July 29, 2026
·
4 min read
Policy
Key Patent Issued for Xyphos Biosciences’ ACCEL™ Technology Platform
Patent Protects Xyphos’ Advanced Cell-based Cancer Therapies
April 16, 2019
·
4 min read
Press Releases
FOXO TECHNOLOGIES INC.’S SUBSIDIARY VECTOR BIOSOURCE, INC. ENTERS INTO DEFINITIVE AGREEMENT TO ACQUIRE FOUR BLOOD COLLECTION CENTERS FROM GRIFOLS BIO SUPPLIES, INC.
July 29, 2026
·
6 min read
Press Releases
Biogen Completes Acquisition of RayThera Inc.
August 7, 2026
·
7 min read
Business
Phenomic Enters into Strategic Research Collaboration with Astellas for Solid Tumor Cell Therapies
Phenomic AI Inc. (“Phenomic”), a biotech company developing therapies for stroma-rich tumors using its scTx® single cell transcriptomics platform, has entered into a strategic research collaboration with Astellas Pharma Inc., “Astellas” through Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas).
November 30, 2023
·
2 min read
1 of 48,436
Next
